Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment
Author:
Funder
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11307-018-1289-5.pdf
Reference46 articles.
1. Jayaram S, Gupta MK, Polisetty RV, Cho WCS, Sirdeshmukh R (2014) Towards developing biomarkers for glioblastoma multiforme: a proteomics view. Expert Rev Proteomic 11:621–639
2. Stupp R, Hegi ME, Mason WP, van den Bent M, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
3. Vidiri A, Pace A, Fabi A, Maschio M, Latagliata G, Anelli V, Piludu F, Carapella C, Giovinazzo G, Marzi S (2012) Early perfusion changes in patients with recurrent high-grade brain tumor treated with bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31:33
4. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SAA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108:3749–3754
5. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions;Signal Transduction and Targeted Therapy;2023-02-27
2. Measurement of Cerebral Oxygen Extraction Fraction Using Quantitative BOLD Approach: A Review;Phenomics;2022-12-05
3. The Tumor and Its Microenvironment as Complementary Sources of Cancer Biomarkers;Biomarkers of the Tumor Microenvironment;2022
4. Metabolic Tumor Microenvironment Characterization of Contrast Enhancing Brain Tumors Using Physiologic MRI;Metabolites;2021-09-29
5. Differences of Angiogenesis Factors in Tumor and Diabetes Mellitus;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3